MedTrace Logo

Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients

NCT03880682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-11-12

No results posted yet for this study

Summary

Chronic hepatitis C virus (HCV) infection, an important cause of morbidity and mortality worldwide, is a significant problem in kidney transplant recipients (KTRs) given its high prevalence in patients undergoing hemodialysis. Interferon based regimens were cornerstone of treatment of HCV infection in the past; however, due to their low efficacy and high rates of adverse effects, they have been abandoned in the new era of direct acting antivirals (DAAs). Several studies demonstrated the efficacy and safety of DAAs, yet data regarding clinical practice of these agents in KTRs is still needed. Therefore, we conducted a study using our registry data to evaluate the efficacy and safety of DAAs in KTRs.

Conditions

  • Kidney Transplant; Complications
  • Hepatitis C, Chronic

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Safak Mirioglu, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

  • Halil Yazici, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

  • Sabahattin Kaymakoglu, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-06-15
Completion
2019-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880682 on ClinicalTrials.gov